Phase 1 Study of Oral PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies– PRT543-01 (NCT03886831)
PRT543 is designed to be an oral, potent, and selective Protein Arginine Methyl Transferase 5 (PRMT5) inhibitor. PRMT5 is believed to mediate cancer progression in solid tumors and hematologic malignancies.
This Phase 1 dose-escalation, dose-expansion study is evaluating PRT543 in patients with advanced cancers who have exhausted available treatment options. The study will enroll patients with certain advanced solid tumors and hematologic malignancies, including:
- Adenoid cystic carcinoma (ACC)
- Splicing mutated tumors solid tumors and myeloid malignancies